Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">On The Wires<ul><li>Neuralstem (<strong>CUR</strong>) announced completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder (MDD). NSI-189 is a new chemical entity and the lead compound in Neuralstem's neurogenic small molecule program. Enrollment was completed ahead of schedule and data are expected in 3Q 2017.</li><li>Glaukos Corporation (<strong>GKOS</strong>) announced the completion of patient enrollment in the pivotal phase of its FDA Investigational Device Exemption trial for the iStent SUPRA Suprachoroidal Micro-Bypass Stent.</li><li>Windtree Therapeutics (<strong>WINT</strong>) announced that data from a preclinical influenza study showed that aerosolized KL4 surfactant reduced lung inflammation and improved overall survival in a well-established preclinical animal model.</li></ul></td> </tr></table>"